Side effects of second-generation antipsychotics: The experiences, views and monitoring practices of Australian child psychiatrists

Australasian Psychiatry

Volumn 16, Issue 4, 2008, Pages 253-262

  Walter, Garry ^a   Delaroche, Amy ^a   Soh, Nerissa ^b   Hunt, Glenn ^a   Cleary, Michelle ^a   Malhi, Gin ^c   Lambert, Tim ^a   Correll, Christoph ^d   Rey, Joseph ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Child and Adolescent Mental Health Services Australia   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Child psychiatrists; Metabolic syndrome; Monitoring; Prescribing practices; Second generation antipsychotics; Side effects

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; AUSTRALIA; BIPOLAR DISORDER; CHILD HEALTH CARE; CHILD PSYCHIATRY; CLINICAL PRACTICE; DEPRESSION; DISRUPTIVE BEHAVIOR; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG USE; FEMALE; HUMAN; MALE; METABOLIC DISORDER; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRESCRIPTION; QUESTIONNAIRE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; CHILD; CHILD PSYCHIATRY; DATA COLLECTION; HUMANS; MENTAL DISORDERS; MIDDLE AGED; TASMANIA; TREATMENT OUTCOME;

EID: 48749117399     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1080/10398560801958549     Document Type: Article

References (66)

1. Aparasu, RR and Bhatara, V. (2005) Antipsychotic prescribing trends among youths, 1997-2002.56, p. 904.
2. Aparasu, RR and Bhatara, V. (2007) Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004.23, pp. 48-55.
3. Cooper, WO, Arbogast, PG, Ding, H., Hickson, GB, Fuchs, C. and Ray, WA. (2006) Trends in prescribing of antipsychotic medications for US children.6, pp. 79-83.
4. Cooper, WO, Hickson, GB, Fuchs, C., Arbogast, PG and Ray, WA. (2004) New users of antipsychotic medications among children enrolled in TennCare.158, pp. 753-759.
5. Patel, NC, Sanchez, RJ, Johnsrud, MT and Crismon, ML. (2006) Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000.12, pp. 221-229.
6. Olfson, M., Blanco, C., Liu, L., Moreno, C. and Laje, G. (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.63, pp. 679-685.
7. Patel, NC, Crismon, ML Hoagwood, K. et al. (2005) Trends in the use of typical and atypical antipsychotics in children and adolescents.44, pp. 548-556.
8. Efron, D., Hiscock, H. Sewell, JR et al. (2003) Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists.111, pp. 372-375.
9. Cheng-Shannon, J., McGough, JJ, Pataki, C. and McCracken, JT. (2004) Second-generation antipsychotic medications in children and adolescents.14, pp. 372-394.
10. Findling, RL and McNamara, NK. (2004) Atypical antipsychotics in the treatment of children and adolescents: Clinical applications.65, pp. 30-44.
11. Jensen, PS, Buitelaar, J., Pandina, GJ, Binder, C. and Haas, M. (2007) Management of psychiatric disorders in children and adolescents with atypical antipsychotics: A systematic review of published clinical trials.16, pp. 104-120.
12. Findling, RL, Steiner, H. and Weller, EB. (2005) Use of antipsychotics in children and adolescents.66, pp. 29-40.
13. McConville, BJ, Sorter, MT, McConville, BJ and Sorter, MT. (2004) Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.65, pp. 20-29.
14. Patel, NC, Crismon, M., Hoagwood, K. and Jensen, PS. (2005) Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents.15, pp. 270-284.
15. Connor, DF, Fletcher, KE and Wood, JS. (2001) Neuroleptic-related dyskinesias in children and adolescents.62, pp. 967-974.
16. Correll, CU, Leucht, S. and Kane, JM. (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies.161, pp. 414-425.
17. Correll, CU and Kane, JM. (2007) One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics: A systematic review.17, pp. 647-655.
18. Correll, CU and Carlson, HE. (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents.45, pp. 771-791.
19. Correll, CU, Penzner, JB Parikh, UH et al. (2006) Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.15, pp. 177-206.
20. Kapetanovic, S. and Simpson, GM. (2006) Review of antipsychotics in children and adolescents.7, pp. 1871-1885.
21. Toren, P., Ratner, S., Laor, N. and Weizman, A. (2004) Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.27, pp. 1135-1156.
22. Fedorowicz, VJ and Fombonne, E. (2005) Metabolic side effects of atypical antipsychotics in children: A literature review.19, pp. 533-550.
23. Bryden, KE, Carrey, NJ and Kutcher, SP. (2001) Update and recommendations for the use of antipsychotics in early-onset psychoses.11, pp. 113-130.
24. Correll, CU. (2007) Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials.46, pp. 687-700.
25. Gracious, BL and Findling, RL. (2001) Antipsychotic medications for children and adolescents.30, pp. 138-145.
26. Stigler, KA, Potenza, MN, Posey, DJ and McDougle, CJ. (2004) Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.6, pp. 33-44.
27. Masi, G., Mucci, M. and Pari, C. (2006) Children with schizophrenia: clinical picture and pharmacological treatment.20, pp. 841-866.
28. Stigler, KA, Potenza, MN and McDougle, CJ. (2001) Tolerability profile of atypical antipsychotics in children and adolescents.3, pp. 927-942.
29. Correll, CU. (2008) Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes.47, pp. 9-20.
30. Safer, DJ. (2004) A comparison of risperidone-induced weight gain across the age span.24, pp. 429-436.
31. Fleischhaker, C., Heiser, P. Hennighausen, K. et al. (2007) Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.114, pp. 273-280.
32. Ratzoni, G., Gothelf, D. Brand-Gothelf, A. et al. (2002) Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study.41, pp. 337-343.
33. Gentile, S. (2006) Long-term treatment with atypical antipsychotics and the risk of weight gain: A literature analysis.29, pp. 303-319.
34. Ebbeling, CB, Pawlak, DB and Ludwig, DS. (2002) Childhood obesity: public-health crisis, common sense cure.360, pp. 473-482.
35. Hong, Y., Jin, X. Mo, J. et al. (2007) Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality-results of prospective analysis for the Atherosclerosis Risk in Communities study.262, pp. 113-122.
36. Martin, A. and L'Ecuyer, S. (2002) Triglyceride, cholesterol and weight changes among risperidone-treated youths: A retrospective study.11, pp. 129-133.
37. Patel, NC, Hariparsad, M. Matias-Akthar, M. et al. (2007) Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics.17, pp. 303-311.
38. Tohen, M., Kryzhanovskaya, L. Carlson, G. et al. (2007) Olanzapine versus placebo in the treatment of adolescents with bipolar mania.164, pp. 1547-1556.
39. Guo, JJ, Keck Jr, PE Corey-Lisle, PK et al. (2006) Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study.67, pp. 1055-1061.
40. Koller, EA, Cross, JT, Doraiswamy, PM and Schneider, BS. (2003) Risperidone-associated diabetes mellitus: A pharmacovigilance study.23, pp. 735-744.
41. Guo, JJ, Keck Jr, PE Corey-Lisle, PK et al. (2007) Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: A nested case-control study.27, pp. 27-35.
42. Koller, EA, Cross, JT and Schneider, B. (2004) Risperidone-associated diabetes mellitus in children.113, pp. 421-422.
43. Bottai, T., Quintin, P. and Perrin, E. (2005) Antipsychotics and the risk of diabetes: A general data review.20, pp. S349-S357.
44. Harrison-Woolrych, M., Garcia-Quiroga, J., Ashton, J. and Herbison, P. (2007) Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study.30, pp. 569-579.
45. Laita, P., Cifuentes, A. Doll, A. et al. (2007) Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents.17, pp. 487-501.
46. Pappagallo, M. and Silva, R. (2004) The effect of atypical antipsychotic agents on prolactin levels in children and adolescents.14, pp. 359-371.
47. Saito, E., Correll, CU Gallelli, K. et al. (2004) A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents.14, pp. 350-358.
48. Staller, J. (2006) The effect of long-term antipsychotic treatment on prolactin.16, pp. 317-326.
49. Anderson, GM, Scahill, L. McCracken, JT et al. (2007) Effects of short-and long-term risperidone treatment on prolactin levels in children with autism.61, pp. 545-550.
50. Becker, AL, Epperson, CN, Becker, AL and Epperson, CN. (2006) Female puberty: Clinical implications for the use of prolactin-modulating psychotropics.15, pp. 207-220.
51. Wudarsky, M., Nicolson, R. Hamburger, SD et al. (1999) Elevated prolactin in pediatric patients on typical and atypical antipsychotics.9, pp. 239-245.
52. Alfaro, CL, Wudarsky, M. Nicolson, R. et al. (2002) Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.12, pp. 83-91.
53. Dunbar, F., Kusumakar, V., Daneman, D. and Schulz, M. (2004) Growth and sexual maturation during long-term treatment with risperidone.161, pp. 918-920.
54. Blair, J., Scahill, L., State, M. and Martin, A. (2005) Electrocardiographic changes in children and adolescents treated with ziprasidone: A prospective study [see comment].44, pp. 73-79.
55. Lambert, TJ. (2007) Switching antipsychotic therapy: What to expect and clinical strategies for improving therapeutic outcomes.68, pp. 10-13.
56. Gonzalez-Heydrich, J., Raches, D., Wilens, TE, Leichtner, A. and Mezzacappa, E. (2003) Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination.42, pp. 1227-1233.
57. Pappadopulos, E., Jensen, PS Schur, SB et al. (2002) "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings.28, pp. 111-121.
58. Newcomer, JW, Nasrallah, HA and Loebel, AD. (2004) The atypical antipsychotic therapy and metabolic issues national survey.24, pp. S1-S6.
59. Buckley, PF, Miller, DD, Singer, B., Arena, J. and Stirewalt, EM. (2005) Clinicians' recognition of the metabolic adverse events of antipsychotic medications.79, pp. 281-288.
60. Ketter, TA and Haupt, DW. (2006) Perceptions of weight gain and bipolar pharmacotherapy: Results of a 2005 survey of physicians in clinical practice.22, pp. 2345-2353.
61. Doey, T., Handelman, K., Seabrook, JA and Steele, M. (2007) Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years.52, pp. 363-368.
62. Clark, NC. (2004) Consensus development conference on antipsychotic drugs and obsesity and diabetes.27, pp. 596-601.
63. Vieweg, WV, Sood, AB, Pandurangi, A. and Silverman, JJ. (2005) Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?.111, pp. 177-184.
64. Correll, CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse effects in children and adolescents.
65. Nasrallah, HA and Newcomer, JW. (2004) Atypical antipsychotics and metabolic dysregulation. Evaluating the risk/benefit equation and improving the standard of care.24, pp. S7-S14.
66. Correll, CU. (2007) Balancing efficacy and safety in treatment with antipsychotics.12, pp. 12-20.